Enabel will work in a consortium of three development agencies to share its expertise to help the African Union upgrade African vaccine production to 60% of needed vaccines in Africa by 2040.
Brussels, 29th November 2022 – As part of the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+), European Commissioner for International Partnerships, Jutta Urpilainen, has signed two letters of intent to contribute to the two main African institutions for public health, the Africa CDC and the African Medicines Agency. This will build bridges between the Partnerships for African Vaccine Manufacturing and MAV+.
15.5 million euro will be invested in the TESS MAV+ project (Technical Support Structure to the Team Europe Initiative for Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa).
This project will support the Team Europe Initiative MAV+ at the level of the EU Directorate-General for International Partnerships and at the level of the African Centre of Disease Prevention and Control.
It will be implemented by a consortium of three European development agencies: Enabel, Expertise France and GIZ. As the lead agency, Enabel will provide specific expertise in the following areas: (1) pharmaceutical regulatory strengthening, (2) technology transfer and intellectual property management and (3) industrial development and engagement with private sector.
“African countries want to produce their own vaccines, which are essential for offering citizens high-quality healthcare. Belgium has much expertise in this area. Via the TESS MAV+ project, we want to share our knowledge and use it to tackle vaccine inequality together with our African and European partners. We also regularly discuss this directly with our African partners, such as yesterday with the Commissioner for Public Health of the African Union.” says Belgium’s Federal Deputy Prime Minister and Minister of Social Affairs and Public Health, Frank Vandenbroucke.
The Belgian government invested 3 million euro in the initiative, the European Commission contributed 10.5 million and Germany 2 million euro.
Enabel experts will assist the EU Directorate-General for International Partnerships as well as EU delegations in Africa to help execute the MAV+ initiative, providing technical input for political dialogue recommendations and strategic orientations.
“This major initiative is a game-changer in the way we cooperate. Its coverage is Africa-coverage and it brings together different stakeholders, from government, private sector and civil society,” says Jean Van Wetter, Managing director of Enabel, “it will ensure countries in Africa have a sound base for local production of quality medical products and do not depend on imports.”
Together with advancing the various work streams of MAV+, an important objective of the TESS is also to support the Partnership for African Vaccine Manufacturing (PAVM) hosted by the African Centre of Disease Prevention and Control. The objective is to upgrade African production to 60% of needed vaccines in Africa by 2040.
Via TESS, Enabel specifically plans to assist PAVM in Research & Development, and higher education and talent development. Additional consultations with PAVM will further define the support.
The European Commission will also grant 5 million euros to AUDA-NEPAD to advance the African Medicines Regulatory Harmonisation (AMRH) program and the operationalisation of the African Medicines Agency (AMA).
Enabel plans to assist AUDA-NEPAD AMRH in its objective to make the recently created African Medicines Agency operational. Through this work we want to promote south-south collaboration and fair pricing of medicines and vaccines.
MAV+ was announced by European Commission President Ursula von der Leyen at the G20 in May 2021, with an initial 1 billion euro backing from the EU budget and European development finance institutions such as the European Investment Bank (EIB). This amount is being enhanced by contributions from EU Member States. To date, over 1.1 billion have been committed. Please find more info on the MAV+ here: Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (europa.eu).
Press contact: Guido Couck, Head of Communications, Enabel, firstname.lastname@example.org, T +32 486 35 00 75
Alysée Raganot, Agence 35°Nord, email@example.com , T. : +33 6 77 26 48 70
Enabel is the Belgian development agency. It implements Belgium’s governmental cooperation. The agency also works for the account of other national and international donors. With its partners in Belgium and abroad Enabel offers solutions addressing pressing global challenges – Climate Change, Urbanisation, Human Mobility, Peace and Security, Economic and Social Inequalities – and promoting Global Citizenship. With 2000 staff, Enabel manages about 170 projects in more than twenty countries, in Belgium, Africa and the Middle East.